On November 5, 2024 Taiho Oncology Inc. reported presentations at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, to be held Dec. 7-10, 2024, in San Diego, CA (Press release, Taiho, NOV 5, 2024, View Source [SID1234647755]). Among these is an oral presentation on data from a phase 1 open-label dose escalation and expansion trial of oral azacitidine plus cedazuridine (ASTX030) in patients with myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) on Sunday, Dec. 8, 2024, at 4:45 p.m. PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing results from an oral azacitidine plus cedazuridine (ASTX030) combination phase 1 open-label dose escalation trial, as well as real-world data from a study examining clinical outcomes among patient with MDS initiating treatment with oral decitabine and cedazuridine versus parenterally administered hypomethylating agents," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. "These data add to the body of evidence for Taiho Oncology’s expanding hematology portfolio and demonstrate our continued commitment to bring innovative therapies to patients with cancer."

Details for both studies and data to be presented can be found below:

Title: Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
Publication Number: 662
Session Name: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS
Session Date: Sunday, Dec. 8, 2024, 4:30 p.m. – 6 p.m.
Presentation Time: 4:45 p.m.
Location: Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG
Presenter: Dr. Guillermo Garcia-Manero

Title: Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Publication Number: 5189
Session Name: 908. Outcomes Research: Myeloid Malignancies: Poster III
Session Date: Monday, Dec. 9, 2024
Session Time: 6 p.m. – 8 p.m.
Location: San Diego Convention Center, Halls G-H
Presenter: Dr. Amer Zeidan